STIA
VRTX icon

Stone Toro Investment Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Stone Toro Investment Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-4,300
Closed -$344K – 208
2013
Q2 		$344K Buy
+4,300
New +$317K 0.21% 136

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stone Toro Investment Advisers's VRTX Position: Q3 2013 in Review

Stone Toro Investment Advisers sold out of Vertex Pharmaceuticals (VRTX) in Q3 2013, closing a stake of 4,300 shares — an estimated $344K sold.

Stone Toro Investment Advisers first reported a position in VRTX in Q2 2013 and held it in 1 quarter. The position peaked at $344K in Q2 2013. 403 funds tracked by Wall St. Rank hold VRTX as of Q3 2013.

  • Stone Toro Investment Advisers reported no remaining Vertex Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Stone Toro Investment Advisers sold 4,300 Vertex Pharmaceuticals shares in Q3 2013, an estimated $344K.
  • Stone Toro Investment Advisers first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Stone Toro Investment Advisers's Vertex Pharmaceuticals position peaked at $344K in Q2 2013.
  • 403 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2013.

Based on Stone Toro Investment Advisers's 13F filing for Q3 2013, filed 12 Nov 2013.